IDIBELL-Bellvitge Biomedical Research Institute

The Bellvitge Biomedical Research Institute (IDIBELL) was created in 2004. It is the foundation that manages the research activities of Bellvitge University Hospital, the Catalan Oncology Institute, the Bellvitge campus of the University of Barcelona, and the public health companies Institut de Diagnòstic per la Imatge (Image Diagnosis Institute) and Banc de Sang i Teixits (Blood and Tissue Bank). The Institute is the core of Biopol, the health research park of Hospitalet de Llobregat, in the South of Barcelona. The president of the IDIBELL’s managing board is the Catalan Minister of Health, Marina Geli. IDIBELL has more than 500 researchers and manages a budget of almost 22 million euros. The Foundation’s main scientific partners are the University of Barcelona, the Catalan Oncology Institute and the Catalan Health Institute (the managing company of the Bellvitge University Hospital). Since March 2009, it is one of the five research centers accredited by the Spanish Ministry of Health.

Website
http://www.idibell.cat/

Subscribe to rss feed

Oncology & Cancer

CRISPR-edited C. elegans identifies vulnerabilities in cancer

A one-millimeter worm, the nematode Caenorhabditis elegans, is an animal model widely used in biomedical research by hundreds of laboratories around the world. Surprisingly, it has approximately the same number of genes that ...

Oncology & Cancer

Semen miRNAs could be non-invasive biomarkers for prostate cancer

Researchers of the Human Molecular Genetics group at the Bellvitge Biomedical Research Institute (IDIBELL), led by Dr. Sara Larriba, in collaboration with Dr. Francesc Vigués and Dr. Manel Castells of the Urology Service ...

Neuroscience

Apathy as an indicator of progression in Huntington's disease

Researchers from the brain cognition and plasticity group of the Bellvitge Biomedical Research Institute (IDIBELL) and the Neuroscience Institute of the University of Barcelona (UBNeuro) have led an innovative study that ...

Medical research

New treatment could improve care for two bone diseases

Researchers from the Bellvitge Biomedical Research Institute (IDIBELL) and the University of Barcelona (UB) have described the ability of an inhibitor of the PI3Kα (BYL719) to block the ectopic bone formation in mice. This ...

Oncology & Cancer

An inflammatory diet correlates with colorectal cancer risk

Researchers from the Molecular Mechanisms and Experimental Therapy in Oncology program (Oncobell) of the Bellvitge Biomedical Research Institute (IDIBELL) and the Catalan Institute of Oncology (ICO), together with the Biodonostia ...

Oncology & Cancer

Researchers describe a new resistance mechanism

Researchers at the Bellvitge Biomedical Research Institute (IDIBELL) and the ProCure Program of the Catalan Institute of Oncology (ICO) published today inCancer Research a study describing a new mechanism in cancer that turns ...

page 1 from 13